Propanc Biopharma, Inc. (PPCB)

Propanc Biopharma Income Statement

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Selling, General & Admin	61.44	57.05	1.29	1.53	1.73	1.58
Research & Development	0.22	0.22	0.25	0.25	0.26	0.23
Operating Expenses	61.66	57.28	1.54	1.78	1.99	1.81
Operating Income	-61.66	-57.28	-1.54	-1.78	-1.99	-1.81
Interest Expense	-0.78	-0.56	-0.67	-0.53	-0.57	-0.45
Interest & Investment Income	0	0	0	0	0.01	0
Currency Exchange Gain (Loss)	-0.13	-0.09	0.02	0.01	-0.04	0.03
Other Non Operating Income (Expenses)	-0.17	-0.12	0.18	-0.53	-0.1	-0.01
EBT Excluding Unusual Items	-62.74	-58.05	-2	-2.83	-2.7	-2.24
Other Unusual Items	-0.66	-0.87	0.05	0.04	-0.02	0.1
Pretax Income	-63.41	-58.92	-1.95	-2.79	-2.71	-2.14
Income Tax Expense	-	-	-0.13	-0.13	-0.05	-0.11
Net Income	-63.41	-58.92	-1.82	-2.66	-2.66	-2.03
Preferred Dividends & Other Adjustments	-	-	0.19	0.47	0.7	0.39
Net Income to Common	-63.41	-58.92	-2.01	-3.13	-3.36	-2.42
Shares Outstanding (Basic)	7	4	-	-	-	-
Shares Outstanding (Diluted)	7	4	-	-	-	-
EPS (Basic)	-9.00	-14.85	-	-	-	-
EPS (Diluted)	-9.00	-14.85	-	-	-	-
Free Cash Flow	-2.11	-0.41	-0.94	-1.11	-1.44	-1.15
Free Cash Flow Per Share	-0.30	-0.10	-	-	-	-
EBITDA	-61.66	-57.28	-1.54	-1.77	-1.99	-1.81
D&A For EBITDA	0	0	0	0	0	0
EBIT	-61.66	-57.28	-1.54	-1.78	-1.99	-1.81

Source: S&P Global Market Intelligence. Standard template. Financial Sources.